CN113453760B - Apol1抑制剂及其使用方法 - Google Patents

Apol1抑制剂及其使用方法 Download PDF

Info

Publication number
CN113453760B
CN113453760B CN201980092356.3A CN201980092356A CN113453760B CN 113453760 B CN113453760 B CN 113453760B CN 201980092356 A CN201980092356 A CN 201980092356A CN 113453760 B CN113453760 B CN 113453760B
Authority
CN
China
Prior art keywords
group
compound
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980092356.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113453760A (zh
Inventor
M·布罗尼
K·加农
K-N·胡
A·梅德克
P·露丝
Y·施
M·什雷斯塔
F·威特科斯
J·曹
J·H·科姆
L·A·达金
F·丹尼斯
W·A·多尔施
A·福捷
M·哈梅尔
E·B·克鲁格
B·莱德福
S·S·南塔库玛
O·尼古拉斯
C·萨伊格
T·J·森特
T·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN113453760A publication Critical patent/CN113453760A/zh
Application granted granted Critical
Publication of CN113453760B publication Critical patent/CN113453760B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201980092356.3A 2018-12-17 2019-12-17 Apol1抑制剂及其使用方法 Active CN113453760B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
US62/780667 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
CN113453760A CN113453760A (zh) 2021-09-28
CN113453760B true CN113453760B (zh) 2024-05-24

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092356.3A Active CN113453760B (zh) 2018-12-17 2019-12-17 Apol1抑制剂及其使用方法

Country Status (35)

Country Link
US (3) US11618746B2 (cg-RX-API-DMAC7.html)
EP (2) EP4782443A1 (cg-RX-API-DMAC7.html)
JP (1) JP7573528B2 (cg-RX-API-DMAC7.html)
KR (2) KR102912203B1 (cg-RX-API-DMAC7.html)
CN (1) CN113453760B (cg-RX-API-DMAC7.html)
AR (1) AR116913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019405477B2 (cg-RX-API-DMAC7.html)
CA (1) CA3121910A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009053A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210383A (cg-RX-API-DMAC7.html)
DK (1) DK3897833T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000116A (cg-RX-API-DMAC7.html)
EC (1) ECSP21052184A (cg-RX-API-DMAC7.html)
ES (1) ES3067546T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897833T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260487T1 (cg-RX-API-DMAC7.html)
IL (2) IL319575A (cg-RX-API-DMAC7.html)
JO (3) JOP20210131A1 (cg-RX-API-DMAC7.html)
LT (1) LT3897833T (cg-RX-API-DMAC7.html)
MA (1) MA54538B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897833T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007152A (cg-RX-API-DMAC7.html)
PE (1) PE20212302A1 (cg-RX-API-DMAC7.html)
PL (1) PL3897833T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897833T (cg-RX-API-DMAC7.html)
RS (1) RS68055B1 (cg-RX-API-DMAC7.html)
SA (1) SA521422270B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105769XA (cg-RX-API-DMAC7.html)
SI (1) SI3897833T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600169T1 (cg-RX-API-DMAC7.html)
TW (1) TWI848031B (cg-RX-API-DMAC7.html)
UA (1) UA128375C2 (cg-RX-API-DMAC7.html)
UY (1) UY38514A (cg-RX-API-DMAC7.html)
WO (1) WO2020131807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) * 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
CN115867543A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
JP2023530271A (ja) * 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CA3179178A1 (en) 2021-02-19 2022-08-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2022401847A1 (en) * 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) * 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
US20260055083A1 (en) * 2022-08-19 2026-02-26 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
TW202613098A (zh) * 2024-07-09 2026-04-01 大陸商上海旭成醫藥科技有限公司 一種APOLs抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104180A1 (en) * 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
WO2008092231A1 (en) * 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2015048301A1 (en) * 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
EP0924209B1 (en) 1997-12-19 2003-05-02 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
WO2007061763A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
CN118127019A (zh) 2018-05-22 2024-06-04 Ionis制药公司 Apol1表达的调节剂
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) * 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CA3171950A1 (en) 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023154314A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
EP4476199A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104180A1 (en) * 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
WO2008092231A1 (en) * 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2015048301A1 (en) * 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds

Also Published As

Publication number Publication date
CN113453760A (zh) 2021-09-28
CA3121910A1 (en) 2020-06-25
UY38514A (es) 2020-07-31
US12060346B2 (en) 2024-08-13
RS68055B1 (sr) 2026-05-29
EP3897833A1 (en) 2021-10-27
JOP20210130A1 (ar) 2023-01-30
CR20210383A (es) 2021-09-22
HRP20260487T1 (hr) 2026-05-22
MA54538A (fr) 2021-10-27
UA128375C2 (uk) 2024-06-26
PT3897833T (pt) 2026-04-22
IL283592B1 (en) 2025-04-01
IL283592A (en) 2021-07-29
LT3897833T (lt) 2026-04-27
WO2020131807A1 (en) 2020-06-25
MA54538B1 (fr) 2026-04-30
SA521422270B1 (ar) 2024-02-18
KR20260020195A (ko) 2026-02-10
SMT202600169T1 (it) 2026-05-12
FI3897833T3 (fi) 2026-04-07
ES3067546T3 (en) 2026-05-22
JP7573528B2 (ja) 2024-10-25
AU2019405477A1 (en) 2021-06-24
US11618746B2 (en) 2023-04-04
US20200377479A1 (en) 2020-12-03
AU2019405477B2 (en) 2025-04-03
TWI848031B (zh) 2024-07-11
US20250042878A1 (en) 2025-02-06
EP3897833B1 (en) 2026-02-04
MX2021007152A (es) 2021-11-03
PL3897833T3 (pl) 2026-06-01
TW202039471A (zh) 2020-11-01
MD3897833T2 (en) 2026-07-31
SG11202105769XA (en) 2021-07-29
CL2021001561A1 (es) 2021-11-26
SI3897833T1 (sl) 2026-05-29
AR116913A1 (es) 2021-06-23
JOP20210129A1 (ar) 2023-01-30
KR102912203B1 (ko) 2026-01-16
PE20212302A1 (es) 2021-12-10
JOP20210131A1 (ar) 2023-01-30
US20230271945A1 (en) 2023-08-31
DOP2021000116A (es) 2021-09-30
ECSP21052184A (es) 2021-08-31
JP2022515369A (ja) 2022-02-18
EP4782443A1 (en) 2026-07-29
IL319575A (en) 2025-05-01
KR20210116483A (ko) 2021-09-27
BR112021011564A2 (pt) 2021-08-31
IL283592B2 (en) 2025-08-01
DK3897833T3 (da) 2026-03-30
CO2021009053A2 (es) 2021-08-09

Similar Documents

Publication Publication Date Title
JP7573528B2 (ja) Apol1の阻害剤及びその使用方法
KR102919170B1 (ko) 알파-1 항트립신 조절인자로서 축합된 트리시클릭 피롤
CN115867532A (zh) Apol1的抑制剂及其用途
CN115715292B (zh) α-1-抗胰蛋白酶调节剂
CN116547287B (zh) Apol1的抑制剂及其使用方法
CN116348447A (zh) Apol1的抑制剂及其使用其的方法
JP6800334B2 (ja) Btk阻害剤を調製するプロセス
WO2021203010A1 (en) Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
WO2021203014A1 (en) Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4423068B1 (en) Rxfp1 agonists
CN120590414A (zh) 一类含氮杂环类化合物、制备方法和用途
AU2019424628B2 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
CN119731183A (zh) 大环化合物作为cftr调节剂的固体形式和其制备
BR112021011564B1 (pt) Inibidores de apol1, composições farmacêuticas e uso dos mesmos
WO2023230609A1 (en) Heterocyclic pad4 inhibitors
EA052148B1 (ru) Конденсированные трициклические пирролы в качестве модуляторов альфа-1-антитрипсина
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
WO2010015585A1 (en) 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant